

- MM, Reichlin M, Evans J; Lupus Nephritis Collaborative Study Group. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. *Kidney Int* 2001;59:2156-63.
5. Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. *Lupus* 2003;12:651-8.
  6. Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, Marcolongo R, Cervera R, et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. *European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol* 1998;16(5):541-6.
  7. Nasr SH, D'Agati VD, Park H-R, Sterman PL, Goyzueta JD, Dressler RM, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. *Clin J Am Soc Nephrol* 2008;3:682-90.
  8. Chin HJ, Ahn C, Lim CS, Chung HK, Lee JG, Song YW, et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. *Am J Nephrol* 2000;20:57-63.
  9. Nishiya K, Chikazawa H, Nishimura S, Hisakawa N, Hashimoto K. Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features. *Clin Rheumatol* 1997;16:70-5.
  10. Cambridge G, Wallace H, Bernstein RM, Weaker B. Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. *Br J Rheumatol* 1994;33:109-14.

**Arpit Bhargava<sup>1</sup>, Luis M. Ortega<sup>2</sup>, Ali Nayer<sup>3</sup>, Víctor Burguera<sup>4</sup>, Katherine Jasnosz<sup>5</sup>**

<sup>1</sup> Division of Nephrology and Hypertension. Allegheny General Hospital. Pittsburgh, Pennsylvania (USA); <sup>2</sup> Division of Nephrology and Hypertension. Allegheny General Hospital/ Temple University School of Medicine. Pittsburgh, Pennsylvania (USA); <sup>3</sup> Division of Nephrology and Hypertension. University of Miami, Florida (USA); <sup>4</sup> Servicio de Nefrología. Hospital General Universitario Ramon y Cajal. Madrid (Spain); <sup>5</sup> Department of Pathology. Allegheny General Hospital. Pittsburgh, Pennsylvania (USA).

**Correspondence:** Arpit Bhargava  
Division of Nephrology and Hypertension.  
Allegheny General Hospital.  
320 East North Ave Pittsburgh, 15221-477.  
Pittsburgh, Pennsylvania, USA.  
lortega@wpahs.org

## C) BRIEF CASE REPORT

### Rapid progression of polycystic kidney disease during treatment with tumour necrosis factor-neutralising antibodies

*Nefrologia* 2014;34(5):681-3  
doi:10.3265/Nefrologia.pre2014.Jun.12600

#### To the Editor,


Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease caused by mutations in genes PKD1 and PKD2, which codify polycystins 1 and 2<sup>1</sup>. The disease usually progresses more quickly in patients with PKD1 involvement, although there is wide interindividual variability, even within the same family. Furthermore, the progression of a given patient is not linear and may occasionally accelerate. Explanations for this

phenotypic variability include the existence of mutations of varying severity, the individual's genetic load, the need for a second genetic hit and the impact of environmental factors or a third hit<sup>2</sup>. From the second hit hypothesis, it is deduced that polycystic kidney disease is phenotypically dominant but molecularly recessive, such that, for a tubular cell to create a cyst, a second somatic mutation in the second *pkd1* or *pkd2* gene would be necessary, as well as the inherited genetic mutation. With respect to the third hit, there is evidence in animal models that inflammation may contribute to the progression of cystogenesis. Tumour necrosis factor (TNF), the quintessential proinflammatory cytokine, decreases the expression of polycystin 2 in mice<sup>3,4</sup>. We reported the evolution of kidney function and volume in a patient with ADPKD treated for more than one year with TNF-neutralising antibodies due to another disease.

#### CASE REPORT

A 35-year-old male diagnosed with HLA B27-positive ankylosing spondylitis in 2011. An abdominal ultrasound displayed multiple hepatic and renal cysts. The right kidney was 18cm and the left kidney was 19cm. Given the lack of a family history of cystic diseases, he was diagnosed with polycystic kidney disease due to *de novo mutation*.


In March 2011, he began treatment with 40mg adalimumab (Humira®) every 15 days. At that time he had: haemoglobin (Hb) 12.4g/dl, creatinine (Cr) 2.3mg/dl, estimated glomerular filtration rate (eGFR) (according to Modification of Diet in Renal Disease) 34ml/min/1.73m<sup>2</sup>, proteinuria 10mg/dl. In September 2011 he had: Cr 3.24mg/dl, eGFR MDRD 23ml/min/1.73m<sup>2</sup>, proteinuria 1.78g/24h (Figure 1). Treatment was discontinued in January 2012 because the patient developed polyneuropathy and purpura. In February 2012 a nuclear magnetic



**Figure 1.** Evolution of renal function over 29 months. MDRD: Modification of Diet in Renal Disease; RMN: nuclear magnetic resonance

resonance (NMR) displayed a right kidney of 18cm (volume of 2450ml) and a left kidney of 18cm (2250ml). In April 2012 the patient began a course of 50mg Golimumab (Simponi®) every five weeks. Six doses were administered and it was discontinued in September 2012 when the patient complained of a notable increase in his abdominal diameter and an umbilical

hernia, which was directly related to the administration of the drug. A final dose was administered in December 2012. In March 2013, another NMR displayed a right kidney of 25.4cm with a volume of 3899ml and a left kidney of 24.1cm with a volume of 2739ml (Figure 2) and a slight increase in a much smaller amount of hepatic cysts.



**Figure 2.** Image comparing kidney size in the nuclear magnetic resonances of 2012 (left) and 2013 (right).

## DISCUSSION

There is no specific treatment for ADPKD. However, various therapeutic approaches designed based on findings in experimental models and clinical observations are being studied. The TEMPO 3:4 trial observed that tolvaptan reduced the growth rate of cysts and the loss of glomerular filtration<sup>5</sup>. It had previously been observed that vaptans slowed down the progression of murine cystogenesis<sup>6</sup>. In clinical trials the mTOR (*mammalian Target of Rapamycin*) inhibitor sirolimus did not stop the growth of renal cysts and everolimus decreased the growth rate, but not kidney function impairment<sup>7,8</sup>. Again the rationale came from preclinical studies in animals<sup>9</sup>. The ALADIN trial demonstrated that long-lasting somatostatin slowed down cyst growth<sup>10</sup>. The choice of somatostatin was based on a case report. A woman with ADPKD received treatment with somatostatin for a pituitary adenoma and her cystic nephropathy improved<sup>11</sup>. In this regard, observations in a single patient may provide guidance on the potential usefulness of a therapeutic action. In *pkd2 +/-* mice, TNF increased cystogenesis and etanercept reduced it<sup>3</sup>. TNF reduced functioning polycystin 2 below a critical threshold as a result of the increased expression of protein FIP-2<sup>3</sup>. Therefore the evolution of the patient whose case we reported during treatment with anti-TNF for a concomitant disease is particularly interesting. During this period, ADPKD progressed rapidly. The eGFR decreased with a slope of -1.1ml/min/month homogenously over time (and the volume of the kidneys increased by a mean of 71% [1938ml]). This progression speed is much higher than that of patients treated with a placebo in recent clinical trials (Table 1)<sup>5,7,8,10,12</sup>. Contrary to experimental observation<sup>3</sup> and the hope placed in the potential efficacy of anti-TNF therapies<sup>4</sup>, there was no evidence of a therapeutic effect, at least at this stage of the disease. Since this was only one clinical case, it is

**Table 1.** Increased kidney volume in patients assigned to the placebo group in large observational studies and clinical trials and in the patient reported

	Increase in total kidney volume	Decrease in eGFR
Grantham (initial volume >1500ml and =30 years) <sup>12</sup>	144ml/year, 6.7%/year	-5.04mL/min/year
Torres <sup>5</sup>	4.4%/year if initial volume <1500mL 6.7%/year if initial volume >1500mL	-3.81mg/mL/year
Walz <sup>7</sup>	319mL/2 years (159mL/year)	-3.8mL/min/year
Serra <sup>8</sup>	140mL/18 months (93mL/year)	-2.33mL/min/year
Caroli <sup>10</sup>	460mL/3 years (153mL/year)	-4.95mL/min/year
This case	1938mL/12 months, 70.6%/year	-13.2mL/min/year

not a definitive observation. In fact, it may be argued that the existence of a systemic inflammatory disease could have contributed to accelerating the disease. Nevertheless, anti-TNF treatment was effective in controlling the activity of ankylosing spondylitis.

In conclusion, we reported the case of a patient with ADPKD treated with anti-TNF therapy due to a concomitant rheumatic disease, whose kidney disease progressed quickly. This case report argues against the efficacy of anti-TNF therapies for treating the human form of ADPKD.

**Conflicts of interest**

The authors declare that they have no conflicts of interest related to the contents of this article.

1. Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. *Clin Exp Nephrol* 2013;17:317-26.
2. Aguiari G, Catizone L, del Senno L. Multidrug therapy for polycystic kidney disease: a review and perspective. *Am J Nephrol* 2013;37:175-82.
3. Li X, Magenheimer BS, Xia S, Johnson T, Wallace DP, Calvet JP, et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. *Nat Med* 2008;14:863-8.
4. Pirson Y. Does TNF-alpha enhance cystogenesis in ADPKD? *Nephrol Dial*

*Transplant* 2008;23:3773-5.

5. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al.; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2012;367:2407-18.
6. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. *Nat Med* 2003;9:1323-6.
7. Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2010;363:830-40.
8. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. *N Engl J Med* 2010;363:820-9.
9. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. *J Am Soc Nephrol* 2005;16:46-51.
10. Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, et al.; for the ALADIN study group. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. *Lancet* 2013;382:1485-95.
11. Ruggenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-lordache B, et al. Safety and efficacy of long-acting somatostatin

treatment in autosomal-dominant polycystic kidney disease. *Kidney Int* 2005;68:206-16.

12. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, et al.; CRISP Investigators. Volume progression in polycystic kidney disease. *N Engl J Med* 2006;354:2122-30.

**Juan A. Martín-Navarro<sup>1</sup>,  
María J. Gutiérrez-Sánchez<sup>1</sup>,  
Vladimir Petkov-Stoyanov<sup>1</sup>,  
Alberto Ortiz-Ardúan<sup>2</sup>**

<sup>1</sup> Sección de Nefrología. Hospital del Tajo. Aranjuez, Madrid.

<sup>2</sup> Servicio de Nefrología. IIS-Fundación Jiménez Díaz. IRSIN. Universidad Autónoma de Madrid.

**Correspondence:** Juan A. Martín Navarro  
Sección de Nefrología. Hospital del Tajo. Avda. Amazonas Central, SN, 28300. Aranjuez, Madrid. (Spain).  
juanmartinnav@hotmail.com

**Non-infectious cloudy peritoneal fluid secondary to lercanidipine**

*Nefrologia* 2014;34(5):683-5

doi:10.3265/Nefrologia.pre2014.Apr.12500

**To the Editor,**

It is well known that certain calcium channel blockers (CCB) can cause cloudy peritoneal fluid not associated to infection (NICPF).

We report what we believe to be the first case of cloudy peritoneal fluid in relation to lercanidipine identified in our country and possibly in Europe.

**CASE REPORT**

The patient was a 59-year-old Caucasian female with chronic renal failure secondary to mesangial proliferative glomerulonephritis. She had high blood pressure and was on treatment with 320mg/day valsartan